Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T

Enrolling by invitation

Conditions studied: HIV

In brief

Long-term follow-up of study subjects who received AGT103-T product in HIV study. The AGT103-T is genetically modified cells that resist infection with HIV causing a depletion of HIV in HIV-infected study participants.

Key facts

Study ID

NCT05529342

Run by

American Gene Technologies International Inc.

People needed

7

Starts

2022-08-29

Expected to finish

2038-09-29

Last updated by the study team

2022-12-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received the investigational product, AGT103-T, in the AGT-sponsored AGT-HC168 clinical trial
• Provided written informed consent, signed and dated by the study participant in the long-term follow-up study

You may not qualify if…

• Did not receive the investigational product, AGT103-T

Where it is running

• Georgetown University — Washington D.C., District of Columbia, United States
• Washington Health Institute — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.